Innovus Pharmaceuticals, Inc, a pharmaceutical company, engages in the development, licensing, and commercialization of non-prescription medicines and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream for penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement for promoting sexual health; and Androferti, a natural supplement to support male reproductive health and sperm quality.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-964-5123
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$23.99 million
Profitability
Miscellaneous
Employees27
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Innovus Pharmaceuticals (OTCMKTS:INNV) Frequently Asked Questions
What is Innovus Pharmaceuticals' stock symbol?
Innovus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "INNV."
How were Innovus Pharmaceuticals' earnings last quarter?
Innovus Pharmaceuticals Inc (OTCMKTS:INNV) announced its earnings results on Tuesday, August, 13th. The company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.47. The firm earned $6.85 million during the quarter, compared to analysts' expectations of $7.65 million. Innovus Pharmaceuticals had a negative net margin of 34.33% and a negative return on equity of 1,618.20%. View Innovus Pharmaceuticals' Earnings History.
When is Innovus Pharmaceuticals' next earnings date?
What price target have analysts set for INNV?
1 analysts have issued 1 year target prices for Innovus Pharmaceuticals' stock. Their forecasts range from $5.00 to $5.00. On average, they expect Innovus Pharmaceuticals' share price to reach $5.00 in the next year. This suggests a possible upside of 138.1% from the stock's current price. View Analyst Price Targets for Innovus Pharmaceuticals.
What is the consensus analysts' recommendation for Innovus Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innovus Pharmaceuticals.
Has Innovus Pharmaceuticals been receiving favorable news coverage?
News articles about INNV stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Innovus Pharmaceuticals earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Innovus Pharmaceuticals.
Who are some of Innovus Pharmaceuticals' key competitors?
Some companies that are related to Innovus Pharmaceuticals include Cassava Sciences (SAVA), Aytu Bioscience (AYTU), Seelos Therapeutics (SEEL), Mateon Therapeutics (MATN), Pain Therapeutics (PTIE), BIOLINERX LTD/S (BLRX), KemPharm (KMPH), Aerpio Pharmaceuticals (ARPO), RegeneRx Biopharmaceuticals (RGRX), Evoke Pharma (EVOK), Kazia Therapeutics (KZIA), AzurRx BioPharma (AZRX), Guardion Health Sciences (GHSI), Sophiris Bio (SPHS) and Soligenix (SNGX).
What other stocks do shareholders of Innovus Pharmaceuticals own?
Who are Innovus Pharmaceuticals' key executives?
Innovus Pharmaceuticals' management team includes the folowing people:
- Dr. Bassam B. Damaj, Pres, CEO & Director (Age 51)
- Mr. Ryan J. Selhorn CPA, VP & CFO (Age 37)
- Mr. Randy J. Berholtz, Exec. VP of Corp. Devel., Gen. Counsel & Sec. (Age 58)
- Mr. Christopher Stella, VP of Operations
- Mr. Robert C. Verfurth, VP of Sales & Marketing
How do I buy shares of Innovus Pharmaceuticals?
Shares of INNV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Innovus Pharmaceuticals' stock price today?
One share of INNV stock can currently be purchased for approximately $2.10.
How big of a company is Innovus Pharmaceuticals?
Innovus Pharmaceuticals has a market capitalization of $5.48 million and generates $23.99 million in revenue each year. The company earns $-8,280,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. Innovus Pharmaceuticals employs 27 workers across the globe.View Additional Information About Innovus Pharmaceuticals.
What is Innovus Pharmaceuticals' official website?
How can I contact Innovus Pharmaceuticals?
Innovus Pharmaceuticals' mailing address is 8845 Rehco Road, San Diego CA, 92121. The company can be reached via phone at 858-964-5123 or via email at [email protected]
MarketBeat Community Rating for Innovus Pharmaceuticals (OTCMKTS INNV)
MarketBeat's community ratings are surveys of what our community members think about Innovus Pharmaceuticals and other stocks. Vote "Outperform" if you believe INNV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INNV will underperform the S&P 500 over the long term. You may vote once every thirty days.
